Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation

Molecular Cancer Research

Volumn 6, Issue 8, 2008, Pages 1326-1336

  Borlak, Jürgen ^a,b   Jenke, Hans Stephan ^c  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c INSTITUT FÜR SEEFISCHEREI   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; C RAF PROTEIN; COMPLEMENTARY DNA; GENOMIC DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RESVERATROL; UNCLASSIFIED DRUG; 3,3',4,4' TETRACHLOROBIPHENYL; 3,4,3',4'-TETRACHLOROBIPHENYL; AROCLOR 1254; CLOPHEN A50; DIOXIN; POLYCHLORINATED BIPHENYL;

ANIMAL CELL; ARTICLE; BINDING KINETICS; BINDING SITE; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; CROSS LINKING; GENE EXPRESSION; GENE INDUCTION; GENETIC ALGORITHM; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL CULTURE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR BINDING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; ANIMAL; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LIVER CELL; LIVER TUMOR; METABOLISM; MOLECULAR GENETICS; SEQUENCE ALIGNMENT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

RATTUS;

ANIMALS; AROCLOR 1254; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELLS, CULTURED; DIOXINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MOLECULAR SEQUENCE DATA; POLYCHLORINATED BIPHENYLS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-RAF; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR CROSS-TALK; RECEPTORS, ARYL HYDROCARBON; SEQUENCE ALIGNMENT; TRANSCRIPTION, GENETIC;

EID: 52449131736     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0042     Document Type: Article

References (46)

1. Aitken A, Howell S, Jones D, Madrazo J, Patel Y. 14-3-3 α and δ are the phosphorylated forms of raf-activating 14-3-3 β and ζ. J Biol Chem 1995;270:5706-9.
2. Wellbrock C, Karasarides M, Marais R. The raf proteins take centre stages. Nat Rev Mol Cell Biol 2004;5:875-85.
3. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 2005;11:185-95.
4. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005;4:677-85.
5. Strumberg D, Seeber S. Raf kinase inhibitors in oncology. Onkologie 2005;28:101-7.
6. Kramer BW, Götz R, Rapp UR. Use of mitogenic cascade blockers for treatment of c-raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer 2004;4:24.
7. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother 2002;3:709-18.
8. Kolch W, Kotwaliwale A, Vass K, Janosch P. The role of raf kinases in malignant transformation. Expert Rev Mol Med 2002;25:1-18.
9. McPhillips F, Mullen P, Monia BP, et al. Association of c-raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001;85:1753-8.
10. Slater EP, Stubig T, Lau QC, Achenbach TV, Rapp UR, Muller R. C-raf controlled pathways in the protection of tumor cells form apoptosis. Int J Cancer 2003;104:425-32.
11. Tanami H, Imoto I, Hirasawa A, et al. Involvement of overexpressed wildtype BRAF in the growth of malignant melanoma cell lines. Oncogene 2004;23:8796-804.
12. Jenke H-S, Deml E, Oesterle D. C-raf expression in early rat liver tumorigenesis after promotion with polychlorinated biphenyls or phenobarbital. Xenobiotica 1994;24:569-80.
13. Ma Q, Lu AYH. Origins of individual variability in P4501A induction. Chem Res Toxicol 2003;16:249-60.
14. Borlak JT, Scott A, Henderson CJ, Jenke H-S, Wolf CR. Transfer of PCBs via lactation simultaneously induces the expression of P450 isoenzymes and the protooncogenes c-Ha-ras and c-raf in neonates. Biochem Pharmacol 1996;51:517-29.
15. Moennikes O, Loeppen S, Buchmann A, et al. A constitutively active dioxin/ aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res 2004;64:4707-10.
16. Kel A, Reymann S, Matys V, Nettesheim P, Wingender E, Borlak J. A novel computational approach for the prediction of networked transcription factors of aryl hydrocarbon-receptor-regulated genes. Mol Pharmacol 2004;66:1-16.
17. Beck TW, Brennscheidt U, Sithanandam G, Cleveland J, Rapp UR. Molecular organization of the human RAF-1 promoter region. Mol Cell Biol 1990;10:3325-33.
18. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878-84.
19. Wingender E, Chen X, Fricke E, et al. The TRANSFAC system on gene expression regulation. Nucleic Acids Res 2001;29:281-3.
20. Ishikawa F, Takaku F, Nagao M, Sugimura T. Rat c-raf oncogene activation by a rearrangement that produces a fused protein. Mol Cell Biol 1987;7:1226-32.
21. Bonner TI, Oppermann H, Seeburg P, Kerby SB, Gunnell MA, Young AC. The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene. Nucleic Acids Res 1986;14:1009-15.
22. Pearson WR, Wood T, Zhang Z, Miller W. Comparison of DNA sequences with protein sequences. Genomics 1997;46:24-36.
23. Bacsi SG, Reisz-Porszasz S, Hankinson O. Orientation of the heterodimeric aryl hydrocarbon (dioxin) receptor complex on its asymmetric DNA recognition sequence. Mol Pharmacol 1995;47:432-8.
24. Nebert DW, Dalton TP, Okey AB, Gonzales FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004;279:23847-50.
25. Fernandez-Salguero P, Pineau T, Hilbert DM, et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995;268:722-6.
26. Schmidt JV, Su GH, Reddy JK, Simon MC, Bradfield CA. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A 1996;93:6731-6.
27. Shimizu Y, Nakatsuru Y, Ichinose M, et al. Benzo(a)pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 2000;97:779-82.
28. Anderson P, McGuire J, Rubio C, et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci U S A 2002;99:9990-5.
29. Weiss C, Faust D, Dürk H, et al. TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38-MAPK-dependent pathway. Oncogene 2005;24:4975-83.
30. Rigby PW, Dieckmann M, Rhodes C, Berg P. Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase. J Mol Biol 1977;113:237-51.
31. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory; 1982.
32. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-7.
33. Gorski K, Carneiro M, Schibler U. Tissue-specific in vitro transcription from the mouse albumin promoter. Cell 1986;47:767-76.
34. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
35. Thum T, Borlak J. Mechanistic role of cytochrome P450 monooxygenases in oxidized low-density lipoprotein-induced vascular injury. Circ Res 2004;94:e1.
36. Borlak J, Dangers M, Thum T. Aroclor 1254 modulates gene expression of nuclear transcription factors: implications for albumin gene transcription and protein synthesis in rat hepatocyte cultures. Toxicol Appl Pharmacol 2002;181:79-88.
37. Borlak J, Hock A, Hansen T, Richter E. DNA adducts in cultures of polychlorinated biphenyl-treated human hepatocytes. Toxicol Appl Pharmacol 2003;188:81-91.
38. Seglen PO. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J Toxicol Environ Health 1979;5:551-60.
39. Dunn JC, Yarmush ML, Koebe HG, Tompkins RG. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J 1989;3:174-7.
40. Borlak J, Thum T. Induction of nuclear transcription factors, cytochrome P450 monooxygenases, and glutathione S-transferase a gene expression in Aroclor 1254-treated rat hepatocyte cultures. Biochem Pharmacol 2001;61:145-53.
41. Berezney R, Basler J, Kaplan SC, Hughes BB. The nuclear matrix of slowly and rapidly proliferating liver cells. Eur J Cell Biol 1979;20:139-42.
42. Pitot HC, Peraino C, Morse PA, Jr., Potter VR. Hepatomas in tissue culture compared with adapting liver in vivo. Natl Cancer Inst Monogr 1964;13:229-45.
43. Reuber MD. A transplantable bile-secreting hepatocellular carcinoma in the rat. J Natl Cancer Inst 1961;26:891-7.
44. Wiebel FJ, Klose U, Kiefer F. Toxicity of 2,3,7,8-tetrachlorodibenzo- p-dioxin in vitro: H4IIEC3-derived 5L hepatoma cells as a model system. Toxicol Lett 1991;55:161-9.
45. Borlakoglu JT, Wilkins JP. Metabolism of di-, tri-, tetra-, penta- and hexachlorobiphenyls by hepatic microsomes isolated from control animals and animals treated with Aroclor 1254, a commercial mixture of polychlorinated biphenyls (PCBs). Comp Biochem Physio C 1993;105:95-106.
46. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.